Microbiologic Characteristics, Serologic Responses, and Clinical Manifestations in Severe Acute Respiratory Syndrome, Taiwan1 by Hsueh, Po-Ren et al.
Microbiologic
Characteristics,
Serologic
Responses,
and Clinical
Manifestations in
Severe Acute
Respiratory
Syndrome, Taiwan
1
Po-Ren Hsueh, * Cheng-Hsiang Hsiao,* 
Shiou-Hwei Yeh,† Wei-Kung Wang,* 
Pei-Jer Chen,* Jin-Town Wang,* 
Shan-Chwen Chang,* Chuan-Liang Kao,* 
Pan-Chyr Yang,* and The SARS Research 
Group of National Taiwan University College 
of Medicine and National Taiwan
University Hospital
2
The genome of one Taiwanese severe acute respirato-
ry syndrome-associated coronavirus (SARS-CoV) strain
(TW1) was 29,729 nt in length. Viral RNA may persist for
some time in patients who seroconvert, and some patients
may lack an antibody response (immunoglobulin G) to
SARS-CoV >21 days after illness onset. An upsurge of anti-
body response was associated with the aggravation of res-
piratory failure.
I
n November 2002, cases of a life-threatening and highly
contagious febrile respiratory illness of unknown cause
were reported from Guangdong Province in southern
China, followed by reports from Vietnam, Hong Kong,
Singapore, Canada, the United States, and other countries
(1–4). This illness was identified as a new clinical entity
and designated as severe acute respiratory syndrome
(SARS) in late February 2003. This disease has a high
propensity to spread to healthcare workers and household
members and may cause outbreaks in the community
(1–4). Recent reports have demonstrated that a novel coro-
navirus, SARS-associated coronavirus (SARS-CoV), is
associated with the pathogenesis of SARS (5–7).
Laboratory diagnostic tests to analyze clinical specimens
for SARS-CoV include reverse-transcriptase polymerase
chain reaction (RT-PCR) specific for RNAand detection of
specific antibody by using indirect fluorescence antibody
and enzyme-linked immunosorbent assays (8,9). However,
data on the timing and intensity of serologic responses
after illness onset and the association of these responses
with clinical manifestations of the disease are lacking.
In Taiwan, the first case of SARS occurred in a busi-
nessman working in Guangdong who was admitted to
National Taiwan University Hospital (NTUH) on March 8,
2003. As of May 18, 2003, a total of 308 probable cases of
SARS were reported by the Center for Disease Control,
Department of Health, Taiwan (10).
The Study
This study included seven Taiwanese patients, treated at
the National Taiwan University Hospital from March 8 to
May 3, 2003, whose illness met the recent Centers for
Disease Control and Prevention (CDC) and World Health
Organization (WHO) case definition for probable cases of
SARS (11,12). The patients were 26–53 years of age, and
six were men. The incubation period ranged from 2 to 12
days. Of the seven patients, four had recently returned
from China: two patients (patients 1 and 7) from
Guangdong Province and two (patients 5 and 6) from
Beijing. In addition, two family members (patients 2 and
3), and one healthcare worker (patient 4) were from a clus-
ter, which had household or healthcare contact with a
SARS patient, and two patients (patient 5 and 6) were from
another cluster, which had close contact with a SARS
patient in an airplane. 
All patients had fever (body temperature >38°C) and
dry cough. Other symptoms included malaise (five
patients), myalgia (five patients), and rigor (four patients).
All but one patient (patient 7) had loose stools or diarrhea
2–10 days after febrile episodes, and five, including the
four cluster Apatients, had aggravating diarrhea 9–14 days
after febrile episodes. The mean interval between onset of
symptoms and hospitalization was 7.3 days (range 4–12
days).
Pneumonia developed in all seven patients, acute respi-
ratory distress syndrome (ARDS) developed in four
(patients 1, 2, 3, and 6), and ventilator support was given
10–12 days after the onset of illness. Pancytopenia com-
patible with hemophagocytosis syndrome developed in
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Wang, Cheng-Hsiang Hsiao, and Po-Ren Hsueh.patient 2. Five patients (patients 2, 3, 4, 5, and 6) received
ribavirin, intravenous corticosteroid (methylprednisolone,
2 mg/kg/d), and intravenous immunoglobulin (IVIG, 1
gm/kg/d for 2 days). Interstitial pneumonia developed in
patient 7, who responded well to ribavirin and antibiotic
treatment. All patients survived.
Urinary antigen detection for S. pneumoniae and
Legionella pneumophila serogroup I was negative in all
seven patients. Serum from patient 5 was positive for
Mycoplasma pneumoniae immunoglobulin (Ig) M
(enzyme-linked immunosorbent assay [ELISA]) antibody
with a fourfold increase in complement fixation (CF) anti-
body titer in acute- (<1:40) and convalescent-phase sera
(1:160). An elevated Chlamydia pneumoniae CF antibody
(1:32) but negative reaction for C. pneumoniae IgM
(ELISA) antibody was found in the acute-phase serum
sample from patients 1 and 6 and in the acute- (1:32) and
convalescent-phase serum (1:32) samples from patients 5
and 7. The antibody titers of acute- and convalescent-
phase serum samples for C. pneumoniae, C. trachomatis,
C. psittaci, and L. pneumophila in the other patients
showed no significant increase. Five patients (patients 1, 2,
4, 5, and 6) had elevated CF antibody levels (≥1:16)
against parainfluenzavirus 1, 2, or 3. Cultures for influen-
za virus, parainfluenzavirus, mumps, respiratory syncytial
virus, adenovirus, enterovirus, herpes simplex virus, vari-
cella-zoster virus, and cytomegalovirus were negative
from various clinical samples of these patients. 
Nucleic acid was extracted from the sputum and serum
samples and the infected Vero E6 cells by using a viral
RNA kit (QIAamp, Qiagen Inc., Valencia, CA). Reverse
transcription polymerase chain reaction (RT-PCR) for
SARS-CoV was performed with 3 sets of primers (IN-6
and IN-7; Cor-p-F1 and Cor-p-R2; and BNIinS and
BNIAs) developed by CDC and WHO Network
Laboratory. The RT-PCR products were analyzed, and the
unique fragment was cloned and sequenced (6,11). RT-
PCR test results for SARS-CoV were positive in oropha-
ryngeal swabs from patients 6 and 7; sputum from patients
1, 2, 3, 4, and 5; and serum specimens from patients 1, 2,
3, 4, 5, and 7. Cultures of all oropharyngeal swabs and
serum specimens were negative. 
Cytopathic effects in the Vero E6 cells were first found
between day 3 and day 4 after injection of serum speci-
mens from patients 3 and 4. The initial cytopathic effect
was focal, with cell rounding, and was followed by cell
detachment. Similar cytopathic effects developed rapidly
(between day 2 and day 3) after subculture. 
Ultra-thin sections were prepared for electron
microscopy by fixing a washed infected Vero E6 cell pel-
let with 2.5% glutaraldehyde and embedding in Spurr’s
resin. The SARS-CoV (range 60–80 nm in diameter) was
identified by electron microscopy (Figure 1 A and B). RT-
PCR from the infected Vero-E6 cells identified the same
amplicon. Sequences of the amplicons from all patients
were identical and were also identical to those from infect-
ed Vero E6 cells. 
The genome of the SARS-CoV (TW-1) (GenBank
accession no., AY291451) strain from patient 3 was 29,729
nt in length. A comparison of TW1 sequences to the
sequences described previously is summarized in the
Table. The number of nucleotide differences between this
TW1 isolate and the Urbani (AY278741), TOR-2
(AY274119), HKU-39849 (AY278491), and CUHK-W1
(AY278554) strains was 6, 3, 12, and 10, respectively.
IgG antibody to the SARS-CoV was detected by a stan-
dard indirect fluorescence antibody assay (IFA) with seri-
al serum specimens from the seven patients. Spot slides for
IFA were prepared by applying the suspension mixed with
SARS-CoV–infected Vero E6 cells from one patient
(patient 4) and uninfected cells. Slides were dried and
fixed in acetone. The conjugates used were goat antihuman
IgG conjugated to fluorescein isothiocyanate (Organon
Teknika-Cappel, Turnhout, Belgium). The starting dilution
of serum specimens was 1:25 (5). Ten serum samples
obtained from 10 pregnant women during routine prelabor
check-ups were used as control sera. Two IVIG products,
one domestic (from Taiwanese donors) and one imported
(Bayer, Leverkusen, Germany), were also tested for the
presence of antibody.
All serum samples from the 10 pregnant women and the
two IVIG products were negative for IgG antibody (<1:25)
to SARS-CoV. Six patients had detectable IgG antibody to
SARS-CoV during the course of illness, and all of them
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Figure 1. Thin-section electron
micrograph of severe acute respira-
tory syndrome-associated coron-
avirus grown in Vero E6 cells. Panel
A shows extracellular viral particles
(arrow) lining the surface of the
plasma membrane. Some spikes
projecting from the envelope of the
virus are seen. Panel B shows
numerous spherical coronavirus
particles (arrow) within dilated cyto-
plasmic vacuoles (arrowhead). had at least fourfold elevation of antibody levels in acute-
and convalescent-phase serum samples (peak levels range
1:400–  ≥1:1600) (Figure 2). Antibody titers (>1:25) of
these six patients could be detected 9–18 days (mean 12.3
days) after the onset of illness. The antibody titer increased
to a plateau 4–10 days after the appearance of antibody.
The high antibody levels might last for 1 to >2 months
after onset of illness (Figure 2). One previously healthy
patient (patient 7) with positive SARS-CoV RNA by RT-
PCR from both sputum and serum specimens had no
detectable antibody to SARS-CoV in serum specimens
obtained 7, 10, 14, and 24 days after illness onset.
Although the antibody levels reached a plateau in all
patients, viral RNA persisted in the serum samples from
patients 1 and 2 and sputum from patients 1 and 4 for 19 to
29 days after onset of their illness. 
Although four patients had received ribavirin, corticos-
teroid, and IVIG treatment in the early stage of the disease,
antibody was detected as early as 10–12 days after the onset
of illness. The peak level of antibody was 1:400 in patients
2 and 6, 1:800 in patient 3, and >1:1600 in patient 1. 
Conclusions
Serologic study indicated that the antibody to SARS-
CoV appeared as early as 9 days after disease onset and
that a high level of antibody could last for 1–2 months after
disease onset. Previous reports indicated that the mean
time for IgG seroconversion was 20 days and may start as
early as 9–10 days. Our finding supported the results of
Peiris et al. (7,12). Levels and appearance of antibody to
SARS-CoV did not seem to be influenced by the use of
ribavirin and immunosuppressive or immunomodulatory
agents (corticosteroid or IVIG, a blood product prepared
from the serum of 1,000 to 15,000 donors per batch) (13).
Third, the long-term persistence (19–29 days after ill-
ness onset) of viral RNA in the serum and sputum speci-
mens of the SARS-CoV-specific IgG seroconverters is an
important finding. Prolonged shedding of viral RNA in
respiratory secretions (11 days after illness onset), plasma
(up to 9 days), and stool specimens (25 days) was docu-
mented previously (6). Further studies are needed to deter-
mine whether the viable viral particles existed in body flu-
ids in the presence of high antibody to the virus. Finally,
one SARS patient, who did not have an underlying coex-
isting condition and did not receive any immunosuppres-
sive agents during hospitalization, did not have detectable
antibody to SARS-CoV 24 days (>21 days) after illness
onset. The serum and sputum RT-PCR for SARS-CoV
were positive in this patient, and the sequence was con-
firmed. Whether the patient was anergic to SARS-CoV
infection is unknown. A later serum sample taken in the
convalescent stage should be tested to determine whether
this patient subsequently seroconverts  (7).
The upsurge of IgG antibody to SARS-CoV and its cor-
relation with the progression of ARDS, necessitating venti-
lator support in four of the seven patients, was evident.
Previous study suggested that an overexuberant host
response rather than uncontrolled viral replication, con-
tributed to severe clinical symptoms and progressive lung
damage (12). Whether the addition of SARS-CoV–specific
antibody in SARS patients further aggravated the preexist-
ing overactive immune-mediated deterioration was unclear. 
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Table. Nucleotide base differences among the TW-1, TOR-2, HKU-39849, CUHK-W1, and the Urbani sequences of SARS-CoV  
SARS-associated coronavirus sequence 
Base  TW-1  TOR-2  HKU-39849  CUHK-W1  Urbani  A. a. change
b 
            TW1/Urbani 
2,601  T  T  C  T  T  Val/Val 
3,165  G  A  A  A  A  Ser/Ser 
7,746  G  G  T  T  G  Pro/Pro 
7,919  C  C  C  C  T  Ala/Val 
9,404  T  T  C  C  T  Val/Ala 
9,479  T  T  C  C  T  Val/Ala 
16,622  C  C  C  C  T  Ala/Ala 
17,564  T  T  G  G  T  Asp/Glu 
17,846  C  C  T  T  C  Arg/Arg 
19,064  A  A  G  G  G  Glu/Glu 
21,721  G  G  A  A  G  Gly/Asp 
22,222  T  T  C  C  T  Ile/Thr 
23,220  T  G  T  T  T  Ser/Ala 
24,872  T  T  T  T  C  Leu/Leu 
25,298  G  A  G  G  G  Gly/Arg 
26867  T  T  T  T  C  Ser/Pro 
27,827  T  T  C  C  T  Cys/Arg 
aSARS, severe acute respiratory syndrome.
 
bIndicates a base difference resulting in an amino acid change. High concentrations of viral RNA, up to 100 million
molecules per milliliter, were detected in a sputum sample
from an index patient on day 9 (6). In the present series, a
physician contracted the infection from a patient (patient
2) 12 days after the onset of symptoms, indicating that
shedding of the virus from the respiratory tract of sympto-
matic SARS patients may last for >12 days. Viral RNA in
the sputum samples of patient 2 collected 12 days after the
onset of symptoms supports this clinical finding. 
Dual infection caused by M. pneumoniae and SARS-
CoV was found in patient 5. No evidence of M. pneumoni-
ae infection existed in patient 6 from the same cluster. This
finding is similar to a previous report (6). Four of our
patients had elevated IgG antibody titers for C. pneumoni-
ae, and five had elevated antibody titers against parain-
fluenzavirus 1, 2, or 3 in acute-phase serum samples with-
out a fourfold rise of titers in convalescent-phase serum
samples. Whether the antibody responses of these patients
reflected past infections from C. pneumoniae, parainfluen-
zavirus, or both, or merely a cross-reaction with antibody
against SARS-CoV virus remains unclear.
As of May 16 2003, data of complete genomic
sequences for 13 SARS-CoV strains isolated from Hong
Kong, Singapore, China, Canada, Vietnam, and Taiwan
were available in GenBank. The number of nucleotides
ranged from 29,705 (SIN2677 strain) to 29,751 (TOR2)
(14,15). Since February 2003, at least three different clus-
ters of SARS outbreaks occurred in different parts of
Taiwan, and five strains were identified from patients in
these clusters. The availability of the sequence data of dif-
ferent strains in a given geographic area will have an
immediate impact on the effort to trace the origins and
transmission of SARS-CoV and develop novel rapid diag-
nostic tests and a vaccine.
In summary, analysis of these seven patients with viro-
logically or serologically documented infections caused by
SARS-CoV in Taiwan not only extended the knowledge of
this emerging novel disease but also provided microbio-
logic and immunologic clues for the physicians caring for
patients suspected of having this disorder. Viral RNA may
persist for some time in patients who seroconvert, and
some patients may lack an antibody response to SARS-
CoV >21 days after illness onset. An upsurge of antibody
response is associated with the aggravation of respiratory
failure that required ventilator support.
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As part of Centers for Disease Control and Prevntion's response to the severe acute respiratory syndrome
(SARS) outbreak, from March 15 through July 17, 2003, quarantine officials at U.S. ports of entry distributed
2,721,965 health alert notices to passengers arriving from areas with SARS. The notices, translated into eight lan-
guages, advised travelers of SARS symptoms and provided physicians with reporting information.